Pikos Symposium 2018

Dr. Richard Miron is currently an Adjunct Professor in the department of Periodontology at Nova Southeastern University in Fort Lauderdale, Florida, USA where he started working in April 2016. He previously worked for 7 years in Bern Switzerland in the Oral Surgery department as head of pre-clinical research under Chair Daniel Buser and Anton Sculean.

He has currently published over 100 peer-reviewed articles and lectures internationally on many topics relating to growth factors, bone biomaterials and guided bone regeneration. He has recently been awarded many international prizes in dentistry and is widely considered as one of the top contributors to implant dentistry having won the International Team for Implantology Andre Schroeder Prize in 2016, the International Association of Dental Research (IADR) Young Investigator of the Year in the field of Implant Dentistry in 2015, and the American Academy of Implant Dentistry Young Investigator of the year award in 2014.

Saturday November 3, 2018

10:30 am – 12:30 pm Dr. Richard Miron

Next Generation Biomaterials for Bone and Periodontal Regeneration

Recently our ability to accurately describe biological events that take place during bone regeneration has drastically been improved by advancements made in the fields of cell and molecular biology. The present talk will discuss the future field of osteoinductive materials including the recent commercialization of the first synthetically fabricated osteoinductive bone graft (OsOpia). Furthermore, the development of a liquid formulation of enamel matrix derivative (Osteogain) for bone and periodontal regeneration, as well as the bone-inducing properties of BMP9 will be discussed. Lastly, advancements in centrifugation protocols will be presented as key modifications to platelet rich fibrin (PRF) therapies.

Learning Objectives:
1. Introduce the research behind new biomaterials and compare their bone-inducing properties.
2. Explain the development of a novel carrier system for enamel matrix derivative (Osteogain).
3. Present an update on the bone-inducing properties of BMP9.
4. Discuss means to optimize platelet rich fibrin (PRF) therapies.